Allergan, Shire Battle In Dry Eye As Generics Advance

 
• By Joseph Haas

Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.

Jousting
As Restasis does battle with Xiidra, generic and pipeline challengers wait in the wings • Source: Shutterstock

More from Sensory

More from Therapy Areas